Simulations Plus (NASDAQ:SLP) Releases FY 2025 Earnings Guidance

Simulations Plus (NASDAQ:SLP) updated its FY 2025 earnings guidance on Tuesday. The company provided EPS guidance of 1.070-1.200 for the period, compared to the consensus EPS estimate of 0.900. The company issued revenue guidance of $90.0 million-$93.0 million, compared to the consensus revenue estimate of $90.7 million. Simulations Plus also updated its FY25 guidance to $1.07-$1.20 EPS.

Simulations Plus Stock Up 4.4 %

NASDAQ SLP traded up $1.29 during trading on Tuesday, hitting $30.39. The stock had a trading volume of 503,863 shares, compared to its average volume of 303,448. The company has a market capitalization of $610.38 million, a PE ratio of 62.02 and a beta of 0.80. Simulations Plus has a twelve month low of $27.07 and a twelve month high of $51.22. The firm has a 50 day moving average price of $29.78 and a 200 day moving average price of $34.16.

Simulations Plus (NASDAQ:SLP) last announced its earnings results on Wednesday, October 23rd. The technology company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.02. Simulations Plus had a net margin of 14.15% and a return on equity of 6.16%. The firm had revenue of $18.70 million for the quarter, compared to the consensus estimate of $19.73 million. During the same period in the prior year, the firm earned $0.18 EPS. The firm’s revenue for the quarter was up 19.9% on a year-over-year basis. On average, sell-side analysts anticipate that Simulations Plus will post 1.1 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on SLP shares. William Blair reiterated an “outperform” rating on shares of Simulations Plus in a report on Wednesday, November 6th. BTIG Research lowered their price objective on Simulations Plus from $60.00 to $50.00 and set a “buy” rating for the company in a research report on Thursday, October 24th. StockNews.com cut shares of Simulations Plus from a “hold” rating to a “sell” rating in a report on Monday, November 4th. Finally, Stephens assumed coverage on shares of Simulations Plus in a research note on Friday, November 15th. They issued an “overweight” rating and a $39.00 price target for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $51.40.

Insider Transactions at Simulations Plus

In other Simulations Plus news, Director Walter S. Woltosz sold 20,000 shares of the company’s stock in a transaction on Friday, November 1st. The shares were sold at an average price of $27.66, for a total value of $553,200.00. Following the completion of the transaction, the director now owns 3,462,584 shares in the company, valued at $95,775,073.44. This represents a 0.57 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 19.40% of the company’s stock.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.